Lysosomes and Their Role in Mucopolysaccharide Disorders: New Insights

Abstract

Mucopolysaccharidoses (MPS) belong to the group of lysosomal storage diseases and are characterized by the deficiency of lysosomal enzymes involved in the degradation of glycosaminoglycans (GAGs). They are caused by inherited enzyme deficiencies that result from mutated genes producing defective enzymes. In MPS, the step-wise degradation process of GAG chains is impaired, and thus pieces of undegraded chains remain in the lysosomes impeding other processes in these cell organelles. Several enzymes—currently 12 are known—are necessary to degrade GAGs to sugars and small chemical substances, such as sulfate- or amino groups, to prepare them for excretion via exocytosis or to reintegrate them into new molecules by recycling. GAGs are major components of the connective tissue but play a role in shaping the vicinity of each cell surface as well; hence, any disturbance in their metabolism causes problems not limited to connective tissue but other tissues and organs. Therefore, MPS are multisystemic diseases involving many organs and restrict a wide range of organ functions. Organomegaly, typical skeletal changes known as “dysostosis multiplex,” excessive storage in the nervous system with neurologic symptoms and impaired cognitive function have been known as the typical symptoms of the first classical MPS types for some time now. Because of new therapies and improved care, the life expectancy of MPS patients has increased significantly. Results of investigations that have only become available recently and new methods allowing for fine-meshed observation have revealed unexpected findings. These outcomes are not limited to excessive storage: patients show unpredictable reactions of the immune system, chronic inflammation, changes in metabolic pathways not directly related to the connective tissue, such as chronic arthritis, osteopenia, Parkinson-like symptoms, signs of dementia, and many more, which suggest that lysosomes have many more roles than just degradation of no longer needed macromolecules.

Keywords

mucopolysaccharide storage disease - lysosome - endosomes - inflammation - autophagy

• References

• 1 Hunter C. A rare disease in two brothers. Proc R Soc Med 1917; 10 (Sect Study Dis Child): 104-116
• 2 Hurler G. Über einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Z Kinderheilkd 1920; 24: 220-234
• 3 Berry HK. Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem 1987; 20 (05) 365-371
• 4 Calatroni A. Test for mucopolysaccharidoses: simple method for quantitative estimation of urinary glycosaminoglycans. Clin Chem 1972; 18 (03) 266-269
• 5 Whiteman P. The quantitative determination of glycosaminoglycans in urine with Alcian Blue 8GX. Biochem J 1973; 131 (02) 351-357
• 6 Hann IM, Lake BD, Lilleyman J, Pritchard J. Storage disorders. In: Colour Atlas of Paediatric Haematology. 3rd ed. Oxford, New York, Toronto: Oxford University Press; 1996: 148-171
• 7 Neufeld EF, Cantz MJ. Corrective factors for inborn errors of mucopolysaccharide metabolism. Ann N Y Acad Sci 1971; 179: 580-587
• 8 Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968; 162 (3853): 570-572
• 9 Fratantoni JC, Hall CW, Neufeld EF. The defect in Hurler and Hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation. Proc Natl Acad Sci U S A 1969; 64 (01) 360-366
• 10 Dorfman A, Matalon R. The Hurler and Hunter syndromes. Am J Med 1969; 47 (05) 691-707
• 11 de Duve C. The lysosome turns fifty. Nat Cell Biol 2005; 7 (09) 847-849
• 12 Neufeld E, Muenzer J. The Mucopolysaccharidoses. In: Scriver CBA, Sly S. , et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001: 3421-3452
• 13 Meyer K. Biochemistry and biology of mucopolysaccharides. Am J Med 1969; 47 (05) 664-672
• 14 McKusick VA. The nosology of the mucopolysaccharidoses. Am J Med 1969; 47 (05) 730-747
• 15 Tomatsu S, Gutierrez MA, Ishimaru T. , et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005; 28 (05) 743-757
• 16 Tomatsu S, Okamura K, Maeda H. , et al. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005; 28 (02) 187-202
• 17 Kircher SG, Bajbouj M, Miebach E, Beck M. Mucopolysaccharidoses - A Guide for Physicians and Parents. London, Boston: UNI-Med Science Verlag Bremen International Medical Publishers; 2007
• 18 de Duve C. Lysosomes revisited. Eur J Biochem 1983; 137 (03) 391-397
• 19 Wartosch L, Bright NA, Luzio JP. Quick guide lysosomes. Curr Biol 2015; 25: R301-R327
• 20 Medina DL, Fraldi A, Bouche V. , et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 2011; 21 (03) 421-430
• 21 Sardiello M, Palmieri M, di Ronza A. , et al. A gene network regulating lysosomal biogenesis and function. Science 2009; 325 (5939): 473-477
• 22 Saftig P, Haas A. Turn up the lysosome. Nat Cell Biol 2016; 18 (10) 1025-1027
• 23 Seranova E, Connolly KJ, Zatyka M. , et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem 2017; 61 (06) 733-749
• 24 Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009; 1793 (04) 684-696
• 25 Ryter SW, Bhatia D, Choi ME. Autophagy: alysosome-dependent process with implications in cellular redox homeostasis and human disease. Antioxid Redox Signal 2018; DOI: 10.1089/ars.2018.7518.
• 26 Appelqvist H, Wäster P, Kågedal K, Öllinger K. The lysosome: from waste bag to potential therapeutic target. J Mol Cell Biol 2013; 5 (04) 214-226
• 27 Markmann S, Thelen M, Cornils K. , et al. Lrp1/LDL receptor play critical roles in mannose 6-phosphate-independent lysosomal enzyme targeting. Traffic 2015; 16 (07) 743-759
• 28 Rigante D, Cipolla C, Basile U, Gulli F, Savastano MC. Overview of immune abnormalities in lysosomal storage disorders. Immunol Lett 2017; 188: 79-85